We then go on to summarize key preclinical and clinical data describing the role of TGF-β as a target for therapeutic intervention in PDAC and HCC, and explore perspectives to optimize TGF-β inhibition therapy. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.